Ivan I. is an accomplished scientist with extensive experience in the biotechnology and life sciences sectors. Currently serving as an Advisor at Eli Lilly and Company since October 2025, Ivan I. transitioned from a Senior Scientist role following the acquisition of Verve Therapeutics, where responsibilities included developing advanced assays for hemoglobinopathies. Previous roles span several companies, including CRISPR Therapeutics, where Ivan I. focused on optimizing stem cell differentiation protocols, and Daktari Diagnostics, where contributions included developing immunoassays for HIV/HCV viral loads. Ivan I.'s career began at Merrimack Pharmaceuticals as a Research Assistant after earning a BS in Biology from Northeastern University in 2009.
This person is not in the org chart
This person is not in any teams
This person is not in any offices